argenx SE rStock

RARGX

Argenx engages in the R&D and manufacturing of antibody drugs for autoimmune diseases. Relying on its immune system platform, the company conducts the screening of protein molecules, clinical trials, and scaled production within bioreactors. The approved liquid biological preparations are primarily supplied in bulk via cold chain logistics to global hospitals, specialty clinics, and medical procurement agencies for physical intravenous or subcutaneous injection treatments in severe patients.